EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study

Michał Brzdęk iD, Piotr Rzymski iD, Dorota Zarębska-Michaluk iD, Barbara Poniedziałek iD, Beata Lorenc iD, Hanna Berak iD, Włodzimierz Mazur, Justyna Janocha-Litwin iD, Magdalena Tudrujek-Zdunek iD, Marek Sitko iD, Jakub Klapaczyński iD, Robert Flisiak

Viruses · 12.07.2026 · 18 (7) · 763

DOI: 10.3390/v18070763 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Viruses, online erschienen am 12.07.2026. Verfasst von Michał Brzdęk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland. Hauptthemen laut MEDLINE: Antiviral Agents, Hypertension, Hepatitis C, Chronic, Hepatitis C. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Arterial hypertension (AH) and hepatitis C virus (HCV) infection are interlinked, with AH increasing the risk of severe liver disease and HCV contributing to cardiovascular issues. Treating HCV in hypertensive patients is critical, though data on direct-acting antivirals (DAAs) in this group remain limited.

Methods

This retrospective study evaluated the effects of DAAs in AH patients with HCV using data from the 2015–2023 EpiTer-2 project, a multicenter study in Poland.

Results

Among the 18,968 HCV-infected DAA-treated patients, 5976 had AH. These patients were older, predominantly women, and had higher rates of obesity, comorbidities, cirrhosis, hepatocellular carcinoma, and genotype 1b infection. Sustained virologic response rates were high and comparable between the AH and non-AH groups in the intent-to-treat (94.8% vs. 94.2%) and per-protocol analyses (97.6% vs. 97.6%). AH was not independently associated with treatment failure (OR 0.87, 95% CI: 0.69–1.10). Predictors of failure included genotype 3, decompensated liver function, cirrhosis, thrombocytopenia, and treatment with asunaprevir + daclatasvir. While therapy discontinuation was more common in the AH patients, most completed treatment, with fatigue being the most frequent adverse event. Although not directly evaluated, the overall safety outcomes suggest that potential drug–drug interactions with antihypertensive therapies are unlikely to have a major clinical impact in routine practice.

Conclusions

This study highlights the safety and efficacy of DAAs in AH patients and emphasizes the importance of early HCV detection and treatment in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHypertensionHepatitis C, ChronicHepatitis CHumansFemaleRetrospective StudiesHepacivirusMaleMiddle AgedAgedSustained Virologic ResponseGenotypeTreatment OutcomePolandValineCarbamatesImidazolesPyrrolidines

Stichwörter der Autor:innen

direct-acting antiviralshepatitis C virushypertensionsustained viral responsetreatment effectivenesstreatment safety

Substanzen

Antiviral AgentsValinedaclatasvirCarbamatesImidazolesPyrrolidines

Autor:innen und Institutionen

  • Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland.
  • Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Poznań, Poland.
  • Department of Infectious Diseases and Allergology, Jan Kochanowski University, 25-317 Kielce, Poland.
  • Pomeranian Center of Infectious Diseases, Medical University, 80-214 Gdańsk, Poland.
  • Outpatient Clinic, Hospital for Infectious Diseases in Warsaw, 01-201 Warsaw, Poland.
  • Clinical Department of Infectious Diseases in Chorzów, Medical University of Silesia, 40-055 Katowice, Poland.

ORCID-Profile: Michał Brzdęk, Piotr Rzymski, Dorota Zarębska-Michaluk, Barbara Poniedziałek, Beata Lorenc, Hanna Berak, Justyna Janocha-Litwin, Magdalena Tudrujek-Zdunek, Marek Sitko, Jakub Klapaczyński

Zitieren

APA

Brzdęk, M., Rzymski, P., Zarębska-Michaluk, D., Poniedziałek, B., Lorenc, B., Berak, H., Mazur, W., Janocha-Litwin, J., Tudrujek-Zdunek, M., Sitko, M., Klapaczyński, J., & Flisiak, R. (2026). Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study. Viruses, 18(7), 763. https://doi.org/10.3390/v18070763

Vancouver

Brzdęk M, Rzymski P, Zarębska-Michaluk D, Poniedziałek B, Lorenc B, Berak H, et al. Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study. Viruses. 2026;18(7):763. doi:10.3390/v18070763

BibTeX
@article{Brzdk2026,
  author = {Brzdęk, Michał and Rzymski, Piotr and Zarębska-Michaluk, Dorota and Poniedziałek, Barbara and Lorenc, Beata and Berak, Hanna and Mazur, Włodzimierz and Janocha-Litwin, Justyna and Tudrujek-Zdunek, Magdalena and Sitko, Marek and Klapaczyński, Jakub and Flisiak, Robert},
  title = {Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {763},
  doi = {10.3390/v18070763}
}
Kostenlos starten →